Compare Kinder Morgan Inc (KMI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Moderna, Inc. — how do they compare? Kinder Morgan Inc trades at $32.56 (market cap $71.81B), while Moderna, Inc. trades at $220.73 (market cap $78.65B). The key difference: Kinder Morgan Inc and Moderna, Inc. are close in size by market cap, and Kinder Morgan Inc pays a 3.66% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Moderna, Inc. for 59 Days on average.
| KMI | MRNA | |
|---|---|---|
Market Cap | $71.81B | $78.65B |
Volume | 16,921,908 | 37,373,437 |
Sector | Energy | Health |
52-Week High | $34.31 | $203.46 |
52-Week Low | $25.84 | $22.36 |
Typical Hold Time | 150 Days | 59 Days |
Enterprise Value | $103.86B | $74.80B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.36, up 1.7% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and consistent earnings beats, while maintaining a 19.31% net income margin. Recent news highlights the company's $6B-$7B growth pipeline and resilience in volatile energy markets.
KMI presents a compelling investment case with analyst consensus target of $37.20 (15% upside), strong dividend yield, and fee-based revenue model. Key risks include energy market volatility and high debt levels, but the company's project backlog and natural gas demand growth support positive long-term outlook.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
